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Abstract
Herpes Zoster (shingles) is a preventable disease that affects 1 in 3 people over
their lifetime. A severely painful complication called post-herpetic neuralgia (PHN)
occurs in up to 20% of people affected with shingles. The Centers for Disease Control
and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP)
recommends and prefers a recombinant zoster vaccine (Shingrix) with a greater than 90%
efficacy rate for preventing shingles for immunocompetent adults aged 50 years and
older. The purpose of this study was to determine the knowledge and practices of the
ACIP's Shingrix recommendations in the practices of Mississippi primary care providers.
The researchers conducted a descriptive, quantitative study using a convenience sampling
of 54 primary care providers from multiple clinics within Mississippi via a voluntary,
anonymous online and emailed survey. A self-developed worksheet was utilized for data
collection analysis.
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CHAPTER I
Dimension of the Problem
Herpes zoster (HZ or shingles) is a localized eruption of painful blisters along
dermatomal lines. It is caused by a latent varicella zoster virus (VZV). Following
childhood chickenpox, VZV lives dormant within the nerves of the host's body for years.
The virus can be reactivated spontaneously or by a condition that decreases the body's
immune system. Potential triggers for reactivation include increasing age, trauma,
surgery, immunosuppressant therapies, emotional or physical stress, and malignancies
(Lecrenier et al., 2018). The most important risk factors for viral reactivation are
immunosenescence (age-dependent decrease in the immune response) and
immunodeficiency (caused by disease or medication). FIZ incidence in 50-59 years of age
is approximately 5 cases per 1000 persons per year. It increases to 10 cases per 1000
persons per year in persons aged 60 years and older and represents half of all HZ cases.
Estimates show that individuals aged 85 years or older have a 50% chance of having HZ
during their lifetime (Lai et al., 2018). This population, along with the
immunocompromised groups, also are at higher risk for developing the most severe HZ
complications (Famuyiro, Smith, & Raji. 2018).
HZ, although painful, is usually a self-limiting disease with treatment targeting
symptom relief. However, HZ has multiple complications. The most common
complication follows a blistering rash and manifests as long-term neuropathic pain called
post-herpetic neuralgia (PUN). PHN occurs in up to 20% of patients and in more than
30% of those who are 80 years of age and older. The pain can be refractory and difficult
to treat (Lecrenier et al., 2018).
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Statement of Problem
Approximately one million HZ cases are reported in the United States (US) with 1
in 3 older adults developing HZ at some point in their lifetime. Previous researchers have
found that an astonishing 99% of all adults aged 40 years and older have serological
evidence of VZV infection and are at risk of developing HZ. Though the varicella
vaccination has been available, HZ incidence has been increasing over the last decades
for reasons unknown. An increase in HZ incidence is expected to continue due to the
compounding effect of aging populations and longer life spans. In 2017, researchers
projected the costs of HZ in the population of 65 years and older at $4.47 billion if the
HZ incidence is not slowed (Famuyiro et ah. 2018).
Initially, HZ appears to be an uncomplicated, yet painful rash, but the infection
can trend toward debilitating illness and significant decrease in the quality of life. HZ
complications contribute substantially to the country's health economic burden
(Lecrenier et ah. 2018). In a 2016 cost analysis for HZ and other vaccine-preventable
diseases, researchers found that approximately 9% ($782 million) of the annual US
economic burden of under vaccination could be attributed to HZ (Famuyiro et ah, 2018).

Statement of Purpose
The purpose of this study was to determine Mississippi primary care providers'
(PCP) knowledge and practices of the Centers for Disease Control and Prevention's
(CDC) Advisory Committee on Immunization Practices (ACIP) recommendations for
administering the Shingrix vaccine to immunocompetent adults aged 50 years and older.
Immunizations are among the most successful public health achievements for prevention
of diseases. The CDC reported the most recent national results (2016) of the National

Health Interview Survey (NH1S) for HZ vaccination rates, influenza vaccination rates,
and pneumococcal vaccination rates in adults aged 60 years and older. Herpes coverage
was JJ.4/o, influenza coverage 70.4%, and pneumococcal coverage 66.9% (Centers for
Disease Contiol and Prevention [CDC], 2018b), "Vaccination acceptance is affected by a
variety of factors, with the single most commonly cited determinant of successful
vaccination being provider recommendation" (Bonville, Domachowske, Cibula, &
Suryadevara, 2017, p. 2645).
Yaqub. Castle-Clark, Sevdalis, and Chataway (2014) performed a literature
review regarding the general population and PC-P attitudes concerning vaccination.
Previous researchers have discovered several limiting factors that affected the PCP's
attitudes such as lack of time, lack of awareness of national guidelines, lack of knowledge
about vaccines, and personal reservations about recommending specific vaccinations
(Yaqub, Castle-Clark, Sevdalis, & Chataway, 2014). Even though most PCPs agree that
ACIP recommendations are important, one study evaluated the attitudes and practices of
physicians in the state of New York and found that HZ vaccination was found to be less
of a clinical priority than influenza and pneumococcal vaccination (Tsui et al., 2018).
Lu, O'Halloran, Williams, and Harpaz (2017) analyzed the results of the 2014
Behavioral Risk Factor Surveillance System. This system assessed national and state
level adherence to the shingles vaccination administration following the United States
Food and Drug Administration (FDA) approval of the shingles vaccine (Zostavax) in
2006. The researchers found that among national and state levels regarding shingles
vaccination in adults aged 60 years and older. Mississippi ranked lowest at 17.8% (Lu.
O'Halloran, Williams, & Harpaz, 2017).

4
Significance of Study
Eftoits at alleviating HZ and its associated complications are ongoing. Prevention
by vaccination is the most cost-effective option (Famuyiro et al., 2018). Since 2006. a
live-attenuated zoster vaccine (ZVL or Zostavax) has been the only HZ vaccine available
to prevent shingles, with a moderate efficacy rate of 51.3% in adults 60 years and older
and J7.6% in adults aged 70 years and older. Zostavax's efficacy rate for PHN prevention
is 66.5% in adults aged 60 years and older. Zostavax's efficacy for HZ prevention and
PHN substantially decreases in the first year, and then tapers to nonsignificant levels after
6 years. In October 2017, the FDA approved a 2-dose subunit adjuvanted recombinant
zoster vaccine (RZV, HZ/su, or Shingrix) for use in immunocompetent adults aged 50
years and older. Following FDA approval, the ACIP reviewed HZ epidemiology and the
evidence for the efficacy, safety, and programmatic factors for RZV and ZVL. "The
majority of ACIP members voted to recommend RZV preferentially" (Dooling et al.,
2018. p. 106).
The recombinant zoster vaccine's efficacy for prevention of HZ is 96.6% in adults
aged 50-59 years, 97.4% in adults aged 60-69 years, and 91.3% in adults aged 70 years
and older. Clinical trials showed the vaccine's efficacy in the first year was 97.6% and
was 84.7% or higher for the remaining 3 years of the study in persons aged >70 years.
Vaccination efficacy for PHN was 91.2% in adults aged 50 years and older and 88.8% in
adults aged 70 years and older. Within the clinical trials, solicited adverse events (AE)
such as injection site pain, myalgia, and fatigue were reported in 16.5% of vaccine
participants compared to 3.1% of placebo recipients. Rates of serious AE were similar in
the RZV and placebo groups (Dooling et al., 2018).
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HZ infection is a significant illness that negatively affects a patient both
physically, socially, and economically, more so if it progresses towards severe
complications that could require intensive treatment such as hospitalization. It is also a
significant financial burden to the US economy. A 2011 savings estimation for cost per
case of prevented HZ was $3,330 and the cost per case of prevented PHN was estimated
to be $6,405 (Evans, 2010). Considering 7 years of inflation, calculating the increased
index value with the past cost results in an estimated increase for cost per case of
prevented HZ as $4,063 and the cost per case of prevented PHN as $7,814 (U.S
Department of Labor, Bureau of Labor Statistics, 2010).
Knowledge and appropriate practice of the ACIP's recommendation for Shingrix
vaccination could decrease the burden of disease to the patient and to the nation. The
current research project was useful in identifying possible factors that are barriers to
knowledge and practice of the ACIP's recommendations for RVZ vaccination in adults
aged 50 years and older, which could be met with continued education, in-services. and
workshops. Improving PCP knowledge and practices related to RZV recommendations
could improve patient health outcomes and decrease costs for individuals, providers, and
the US economy.
Theoretical Framework
Nola J. Pender's Health Promotion Model (HPM) was used to guide this research
study. Theoretical models of nursing can be used not only to assist in understanding the
behaviors of patients, but also in understanding the behaviors or practices of PCPs.
Pender's HPM will be influential in this research study by revealing factors contributing
to PCPs' health promoting practices.
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The goal of the current study was aimed at evaluation of PCPs" practice regarding
their knowledge and practice of ACIP guidelines that can result in increased health status
for an individual and decreased costs in healthcare. HPM is a foundational model in
changing practices and promoting healthy behavior and choices. Health promotion can
lead to healthy behavior, increased health status and decreased cost in healthcare. This
model provides a useful theoretical framework for research aimed toward improving
health and detecting health promoting behaviors (Heydari & Khorashadizadeh, 2014).
Pender's HPM focuses on helping individuals achieve a higher level of wellness
and identify factors influencing or hindering healthy behavior. PCPs are encouraged to
provide resources to help individuals achieve behavior changes to promote wellness. The
goal of the HPM is not only preventing illness through behavioral changes, but to identify
and educate PCPs and individuals on interventions that promote health (Khoshnood,
Rayyani. & Tirgari, 2018).
Major determinants of health promotion and quality ol life practices are identified
by the HPM as cognitive and perceptual factors. The promotion of health is motivated by
the desire of one to enhance wellness and actualize human potential. Pender claims
individuals are motivated to engage in behaviors or piactices that promote health by
biopsychological processes. There are fourteen theoretical assertions from the HPM. This
research study considered four of the fourteen assertions as follows, (a) perceived
benefits of action; (b) perceived barriers of action, (c) peiceived self-efficacy, and (d)
activity-related affect (Alligood, 2018).
Perceived benefits of action are defined as the anticipated positive outcomes
arising from health promoting practice. Perceived barriers to action are defined as
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anticipated, leal, and personal cost or hinderance associated with the health promoting
practice. Peiceived self-efficacy is defined as the discernment of one's capability to
organize and conduct a health promoting practice. Activity-related affect describes one's
positive 01 negative feelings before, during, and after the health promoting practice
legarding the practice itself. There is a correlation among these four assertions. Activityrelated affect influences the perceived self-efficacy, and increased self-efficacy
influences a further positive affect. Also, perceived self-efficacy influences perceived
barriers to action, meaning a higher self-efficacy lowers the perception of barriers
associated with the health promoting practice (Alligood, 2018).
Pender s HPM can be used to assist PCPs in recognizing perceived benefits and
barriers of adherence to the AC1P guidelines regarding HZ vaccination. It can also assist
PCPs in determining one's self-efficacy and activity-related affect. Utilizing Pender's
HPM. the research study intends to make adherence to the ACIP guidelines appear
beneficial to the PCP and the patient. Evaluation of the PCP activity-related affect
regarding the guidelines and vaccination has the potential to increase the PCP selfefficacy of adherence, and in turn can decrease the perception of any barriers to the
guidelines and vaccination increasing adherence. Highlighting or exposing the activityrelated affect and self-efficacy of Mississippi PCPs has the potential to impact current
practices and healthy promotion for individuals within the state.

Research Questions
The current research study was based on the following questions for the scope of
this study:
1. Are Mississippi primary care providers knowledgeable about the Advisory
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Committee on Immunization Practice's Shingrix recommendations for patients
age 50 years and older?
2. What are the Shingrix practices of Mississippi primary care providers?
Definition of Terms
For the purposes of this study, the following terms were defined with theoretical
and operational definitions, respectively:
Primary Care Providers.

Theoretical: Licensed medical personnel, such as a physician (M.D. - Medical
Doctor or D.O. - Doctor of Osteopathic Medicine), nurse practitioner, or physician
assistants allowed under state law, who provide and coordinate a range of health care
services for patients ("Primary Care Provider," n.d.)

Operational: Physicians, nurse practitioners, or physician assistants that practiced
within the state of Mississippi, provided care to patients aged 50 years and older, and
responded to the survey.
Advisory Committee on Immunization Practices (ACIP).

Theoretical: ACIP is a group of fifteen voting members responsible for making
vaccine recommendations (CDC, 2018a).

Operational: ACIP meets three times a year at the Centers for Disease Control
and Prevention in Atlanta, Georgia to review scientific data and vote on vaccine
recommendations.
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Shingrix.

Theoretical. A new shingles 2-dose recombinant vaccine, licensed by the hood
and Drug Administration and recommended for healthy adults 50 years and older that
provides strong protection against shingles and PHN (CDC, 2018c).

Operational. T h e v a c c i n e , S h i n g r i x , p r e s c r i b e d b y t h e s u r v e y e d M i s s i s s i p p i
primary care providers within our study to prevent the risk of shingles and PHN in adults
aged 50 years and older in their practice.
Assumptions
The current researchers made three assumptions about the study. These
assumptions are listed as follows:
1. The responders to the research survey are willing participants.
2. Primary care providers will respond to the survey questions with honesty about
their awareness and adherence to their practices regarding the Shingrix
vaccination.
3. Primary care providers' awareness and adherence to the current Shingrix
recommendations will vary.
Limitations of Study
A major limitation of this study was a small sample size due to lack of survey
response. This study relied on PCPs' self-reporting instead of a calculated measurement
from chart reviews that impartially document the PCPs' practices or observed practices.
Another limitation was the inability to generalize results based on the sample participants
not being representative of all providers collected at a single point in time due to the
study being restricted to Mississippi and PCPs.

CHAPTER II
Literature Review
The review of literature was performed to determine the awareness and adherence
of PCPs to the CDC guidelines for vaccinating immunocompetent adults aged 50 years
and older with the 2-dose recombinant HZ vaccine Shingrix. This following review of
literature will discuss pertinent topics, such as the conceptual framework related to
Pender's HPM and a review of related literature, 'lire review of related literature is
further divided into sections that include vaccine effectiveness, cost effectiveness, and
barriers to adherence. The sections of vaccine effectiveness and cost effectiveness
support the importance of PCPs" awareness and adherence to the CDC's recommendation
and preference for the newer HZ/su vaccine. The barriers section identifies areas that can
be targeted for increased adherence to the recommendation.
Vaccine Effectiveness
Lai et al. (2018) performed a randomized, open-label, multicenter study for
assessing the immunogenicity, reactogenicity, and safety oi HZ/su administered at 2-, 6and 12-month intervals after an initial dose to adults aged 50 years and older. Previous
results in the phase 111 clinical trials for HZ/su showed the administration of two doses at
2 months apart resulted in reduced risk with an efficacy of HZ prevention at 97.2% in
adults aged 50 years and older and 91.3% in adults aged 70 years and older. Assessing
the response to 6-and 12-month interval dosing could provide more flexibility to both
health-care providers and patients for completing the 2-dose schedule. The researchers
posed two hypotheses. The first hypothesis was that the post-dose 2 at the 6-month and
12-month intervals would be as immunogenic as post-dose 2 at the 2-month dosing
10
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interval. The second hypothesis was that the 1 IZ/su vaccine would be safe with expected,
common side effects or AE.
Between March 12, 2013 and April 8, 2015 within the US and Estonia, 354 adults
aged 50 years and older were randomized 1:1:1 in an open-label study across three age
strata (50-59 years, 60-69 years and >70 years) to receive two I IZ/su doses 2-, 6-, or 12rnonths apart. The participants were comprised mainly of Caucasian/European heritage
females with the mean age of 64.5, 64.0, and 64.1 years in Gr 0-2, Gr 0-6, and Gr 0-12
respectively at dose 1. Adults age 50 years and older were included in the study but
excluded it any investigational or non-registered product had been consumed, if any live
or non-replicating vaccination had been administered or planned to be. had a history of
HZ, had received previous vaccination for varicella or 11Z, or had a reactive history or
hypersensitivity to components of the vaccine. Other exclusionary factors were
administration of immunosuppressants or other immune-modifying drugs 6 months
before the initial dose, as well as a condition from disease or therapy that suppressed the
immune system. Risk of pregnancy of female participants had to be ruled out by a
negative pregnancy test on the day of vaccination, fulfilling contraceptive requirements to
protocol specificity, or inability to bear children (Lai et ah, 2018).
Lai et al. (2018) concluded that immune responses at the 0- and 6-month schedule
were non-inferior to the 0- and 2- month schedule based on blood samples measured at
these time points and their resulting statistical significance. This comparable
immunogenicity at the 6-month dosing interval allows for dosing flexibility with the
HZ/su vaccination schedule. In turn, researchers pose this flexibility could increase
vaccination compliance by aligning with routine physician visits instead of non-routine
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\ isits. Along with immune efficacy, researchers reported the HZ/su has an acceptable
salety profile tor all closing intervals. The safety/reactogenicity assessment revealed the
most common AEs were injection site pruritis (2.5% in Gr 0-2), erythema (2.5% in Gr 06), and injection site pruritis and arthralgia (1.7% in Gr 0-12). Serious AEs occurred in
very few participants and were not related to the vaccine (Lai et al., 2018).
Dooling et al. (201 8) analyzed a report summarizing recommendations presented
by the AC1P concerning uses of the HZ vaccines. The researchers identified two
vaccines to prevent HZ: RZV (Shingrix), a 2-dose subunit vaccine approved for use in
adults >50 years of age, and ZVL (Zostavax), a 1-dose live attenuated strain of VZV
licensed for use in immunocompetent adults >60 years of age. The ACIP recommends
use of RZV in immunocompetent adults aged >50 years of age, whereas
recommendations for use of ZVL is in immunocompetent adults aged >60 years of age.
Dooling et al. (201 8) sought to determine the differences in effectiveness between
RZV and ZVL when used to vaccinate immunocompetent adults >50 years of age against
the HZ virus. Currently, ZVL is recommended for adults >/=60 years of age who are
immunocompetent. The ACIP was presented with three proposed recommendations at the
October 201 7 meeting that were ultimately approved by its 15 voting members. These
recommendations were as follows: (a) 14 to 1 favoring RZV recommended for
immunocompetent adults >50 years of age; (b) 12 to 3 favoring RZV recommended for
immunocompetent adults who were previously vaccinated with ZVL, and (c) 8 to 7
favoring RZV preference to ZVL.
The ACIP Herpes Zoster Vaccines Work Groups deemed the outcomes of
prevention of LIZ and PHN as critical, while outcomes deemed important included
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duration of protection and reactogenicity. Outcomes comparing no vaccination to RZV
and ZVL were addressed. No direct comparison between the two vaccines were
conducted (Dooling et al., 2018).
A two-part, phase III multicenter clinical trial, involving the enrollment of
>30,000 participants was conducted. The participants randomly received RZV or a saline
placebo. I arget groups were individuals from two different age groups, adults 50 years
of age and older and adults 70 years of age and older. The Zoster Efficacy Study
documented a median follow-up time of 3.2-3.7 years, yielding the following efficacy
rates: (a) prevention of HZ—96.6% for those 50-59 years of age and 97.4% for those 6069 years of age; (b) vaccine efficacy—84.7%-97.6% for those >70 years of age; this
includes the first year after activation and the remaining 3 years of the study; and (c)
prevention of PHN—91.2% for those >50 years of age and 88% for those >70 years of
age (Dooling et ah, 2018).
Dooling et al. (2018) also addressed how RZV is more cost effective compared to
ZVL, with separate studies conducted by the CDC and GlaxoSmithKline to support this
notion. However, a study conducted by Merck suggests ZVL is more cost effective.
GlaxoSmithKline sponsored eight studies related to serious AE that concluded similar
overall rates for RZV and placebo groups. Pain, myalgia, and fatigue were the most
common solicited adverse reactions. Concurrently, the performance of ZVL was
evaluated using two randomized clinical trials and seven observational studies for
participants >50 years of age. A randomized clinical trial and a modeled control group
were used to evaluate the duration of protection. This study was conducted following an
11-year period. Results concluded a substantial decrease in effectiveness one year after
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receiving ZVL. I his decrease continued and proved no longer statistically significant 911 years after vaccination.
Although RZV has been licensed for all persons >50 years of age. Dooling et al.
(2018) identified that some populations should not receive RZV. Those persons excluded
oi not evaluated in this study include ones who are receiving moderate to high doses of
immunotherapy or those who presently have an immunocompromising illness, persons
who are VZV seronegative, and pregnant or lactating women. There are ongoing studies
for these populations, therefore, caution should be used to ensure the patient's safety and
well-being are not further compromised. Longitudinal and observational studies will be
used to assess long and short-term effectiveness of RZV. The CDC will monitor
coverage of RZV, adherence to the 2-dose schedule, and AE following immunizations.
GlaxoSmithKline will conduct studies to monitor post-marketing safety monitoring due
to the high reactogenicity and immunogenicity of RZV (Dooling et al., 2018).
James, Chahine, Sucher, and Hanna (2018) performed a literature search through
PubMed summarizing the review of the immunogenicity, efficacy, and safety data for
HZ/su and recommendations by ACIP for its use. Two vaccines are currently available
for the prevention of HZ, Zostavx and Shingrix. Zostavax, approved by the FDA in May
2006, is a live, attenuated vaccine approved for use in all eligible persons 60 years and
older, regardless of zoster history. HZ/Su, approved by the FDA in 2017, is an inactive
recombinant subunit vaccine comprising varicella zoster vaccine glycoprotein E (gK) that
is reconstituted at the time of use with AS01B adjuvant suspension. It is approved for use
in the prevention of HZ in adults 50 years and older.
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James et al. (201 8) desired for HZ/su to be included in both hospital and
community pharmacy formularies, as well as to supersede the previous recommendation
of vaccination with ZVL. 1 his literature search sought to determine efficacy in HZ/su
vaccine. HZ/Su has shown to have more beneficial effects in comparison to ZVL. A
reduction in PHN is one of the benefits of HZ/su versus ZVL. PHN is a painful
complication of the shingles virus, which can have long-lasting effects.
James et al. (201 8) performed a review of five different studies. The first was a
randomized, open-label study of HZ/su in patients aged 50-70 years who had no previous
vaccination. Evidence from this study shows cellular and humoral immune response rates
were higher and remained elevated with HZ/su after 42 months. Two other randomized,
observer-blind studies were conducted on immunocompromised persons. These
individuals were not previously vaccinated with, nor had known exposure to VZV or
were HIV positive. Compared with saline placebo, those who received HZ/su had higher
cellular and humoral immune responses that remained elevated for at least one year. A
third randomized, observer-blind study tested adjuvanted and unadjuvanted HZ/su in
immunocompetent persons older than 60 years of age. Immune response results were
higher for adjuvanted HZ/su compared with the unadjuvanted HZ/su.
Finally, a randomized, double-blind placebo-controlled study was conducted.
Patients would receive either two intramuscular doses of I IZ/su or placebo separated by 2
months. Cases of patients aged 70 years and older developing PHN were also identified
during this study. The researchers concluded that HZ/su produced a significant reduction
in the risk of HZ and PHN in adults aged 70 years and older. The researchers highlighted
the long-term protection when immunized with the Shingrix vaccine. Both physicians
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and pharmacists can counsel and give clients information about the Shingrix vaccine,
which aids in making a more informed decision about vaccination (James et ah, 2018).
Shingrix is the preferred vaccine for the prevention of the HZ virus based on
recommendations from the ACIP. Raedler (2018) analyzed a report of the phase clinical
trials that ultimately encouraged the approval of the Shingrix vaccine by the
FDA. Shingrix is an adjuvanted zoster vaccine recombinant approved for the prevention
of the HZ infection. These two studies, the ZOE-50 study and the ZOE-70 study, are
analyzed in this report. The researcher identified the effectiveness of Shingrix against the
HZ infection. HZ, also referred to as shingles, is caused by the VZV and presents as a
painful outbreak seen on the face and body. Affecting approximately 1 million people
each year, shingles poses an increased risk to those with weakened immune systems
(Raedler, 201 8).
The ZOE-50 study was performed in 18 countries, consisting of thousands of
participants aged 50 and older. I hese participants were divided into J age-gioups. (a) 5059 years, (b) 60-69 years, and (c) >70 years (Raedler, 2018). In more than 97% of the
participants, Shingrix was proven effective compared to a placebo, and a significant
reduction in PHN was also observed. In the ZOE-70 study, participants were divided into
2 groups: (1) 70-79 years, and (2) >80 years. A significant reduction risk of HZ for
approximately 90% of these participants was observed compared to a placebo. In both
clinical trials, participants received 2 doses of either Shingrix or placebo (Raedler, 2018).
Raedler (2018) concluded that Shingrix is effective in the prevention of herpes
zoster in those aged >50 years of age. It also provides protection against PHN pain.
Previous researcher concluded there is no data to determine risk with Shingrix if
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administeied to pregnant women. No information is available to determine effectiveness
in persons <18 years of age. However, the ACIP does recommend its use for healthy
individuals aged >50 years of age, as well as individuals previously vaccinated by
Zostavax, a 1-dose live attenuated vaccine also approved for the prevention of 1IZ.

Cost Effectiveness
Le and Rothberg (2018) compared the cost-effectiveness of the adjuvanted heipes
zoster subunit vaccine (HZ/su) to the live attenuated herpes zoster vaccine (ZVL). The
HZ/su was developed to address ZVL's shortcomings, particularly its complete waning of
efficacy after 10 years. The ACIP would have to choose the preferred vaccine, because
insurance plans would require a recommendation for coverage. The ACIP previously
examined the cost-effectiveness of the two vaccines using models developed by the
manufacturers of the HZ/su and the ZVL. Both models showed HZ/su to be cost saving
compared to ZVL. The authors used an independent model without pharmaceutical
funding. Examining cost-effectiveness can also aid PCPs and patients in their choice of
vaccine with the best value.
Le and Rothberg (2018) used a Markov decision model with transition
probabilities using data from PubMed and an updated pievious study and conducted the
study from a societal perspective. The researchers extracted data from these souices that
were from participants groups that consisted of less than 100 to more than J0,000. The
number was dependent on the variable being assessed. Participants in this study were
immunocompetent adults 60 years or older. The study lasted from July 1 to July 31, 2017.
The primary outcomes and measures were total costs and quality-adjusted life-years
(QALYs). To assess costs and QALY's, the researcher's variables for model inputs were
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epidemiology inputs, vaccine efficacy and AE inputs, efficacy function for PUN
incidence, and utility and cost inputs.
Le and Rothberg (2018) looked at the cost-effectiveness for three groups: (a) no
vaccination; (b) vaccination with ZVL; and (c) vaccination with HZ/su. Within these
groups, the researchers further subdivided them into age groups due to the varying costeffectiveness of ZVL at vaccination age. The three age groups were 60-year-olds, 70year-olds, and 80-year-olds. The researchers concluded that "HZ/su was more effective
and less expensive than ZVL for adults 60 years and older." (Le and Rothberg, 2018, p.
256). The projected cost of HZ/su was $280 per series ($140 per dose), making it less
than ZVL's current price of $213 per dose for adults 60 years or older with a high costeffectiveness at $50,000 per QALY for 60-year-olds.
Due to HZ/su's superior efficacy and cost-effectiveness, Le and Rothberg (2018)
declared that the ACIP should recommend a preference for HZ/su over ZVL. The
researchers for this study, also identified HZ/su's single dose efficacy and its potential to
mitigate low adherence rates. HZ/su is a 2-dose vaccine, which can create a barrier to
vaccination adherence. The researchers reported cost-effectiveness, even if 95% of
patients only received the first dose. The researchers suggested that future studies should
be aimed at examining the effectiveness and the waning rate of a single dose, and that
better define efficacy duration, serious reactions, and adherence rates to measure precise
ICER estimates for HZ/su"s cost-effectiveness compared to ZVL. The researchers stated
that the results of these future studies would not change their conclusions. If no
preference is expressed, the researchers stated that avoidable cases of HZ and PHN will
occur among vaccinated pts when a more effective vaccine could have been received.
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W ithout the ACIP s recommendation, physicians, patients, or insurers could be steered
into choosing a vaccine with less value and effectiveness.
Practice Barriers
O Donnell, Shurpin, and Janotha (2018) performed a two-phase study for the
purpose of determining nurse practitioner (NP) barriers to the use of herpes zoster
vaccine (HZV) and implementing the results to develop and evaluate the outcomes of an
educational program. Although it is recommended by the CDC for immunocompetent
adults 50 years of age and older and its efficacy has been demonstrated, HZV usage
continues to he low. According to the CDC and multiple other studies reviewed by
O* Donnell et al. (2018), 99% of people over age 50 in the US have serologic evidence of
varicella virus and reactivation. Reactivation results in HZ, a virus that travels on a nerve
root causing a painful rash. The complication of HZ. PHN, occurs 18% of the time. PHN
is damage to the nerve tissue causing disabling pain long after the rash is resolved. After
the age of 50, due to the natural decline in immunogenicity of aging. HZ incidence
increases with as many as 3% requiring hospitalization. Studies reviewed also reveal
concerns of cost for the patient and provider, safety, and lack of knowledge regarding
HZV continue to present as barriers.
O'Donnell et al. (2018) discovered in Phase I. 50% of the patients were eligible
for HZV, and more than 50% of the surveyed NPs gave 0-9 HZV in the previous twelve
months. The three main barriers identified in Phase 1 were up-front HZV purchasing cost
(46%). concern for patient cost (39%), and concerns of reimbursement issues (29%).
Phase II revealed a statistical difference in scores of the pretest and posttest regarding NP
understanding on HZV. The results of this two-phase study confirmed NPs face similar
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barriers as physicians regarding approving the HZV as recommended by the CDC. The
primary banier is identiiied as a lack of knowledge in multiple areas concerning the
HZV. 1 he study contributed additional evidence to the need of continued education and
dish ibution o! infoimation on HZV to healthcare providers (HCP). The documented
increase in provider knowledge following the educational program gave further evidence
to the lack of knowledge regarding HZV and the benefits of education.
Tsui et al. (2018) performed a cross-sectional online survey for evaluating the
knowledge, attitudes, and practices for the HZ vaccine of providers within five of the
NYU Langone Health (NYULH) clinics. Because HZ infects 1 in 3 people in their
lifetime, and 1.2 million cases develop each year, the researchers cited the organizations
that recommend vaccination against HZ for individuals aged 50 years and older: the
American Academy of Ophthalmology (in 2016), the American Dermatological
Association (in 2017), and the FDA (in 2011). The researchers stated that the CDC has
maintained its recommendation for HZ vaccination in the 60 years and older population.
However, since the researcher's study, the CDC has expanded its recommendation to
include the 50 years and older age group. Vaccination provides protection from infection
and its potential complications, yet vaccination rates remain lower compared to the
annual influenza vaccine or pneumococcal vaccine.
The researchers previously studied the variables via survey in 2011 before
interventions, such as education, availability, and electronic health record alerts were
introduced into the clinics. A one-year follow-up survey after intervention
implementation showed an increase in physician knowledge and vaccine administration.
The researchers desired to investigate again the current knowledge, attitudes, and practice
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patterns of HZ vaccination in context of the previously stated interventions, the FDA
approval of 50->eais and older age expansion lor HZ vaccination, great HZ vaccination
availability, television commercial advertising, and the consistency of the HZ
vaccination's safety and efficacy (Tsui et ah. 2018).
The inherent questions within this study are included: (a) Are NYULH physicians
aware of the CDC and hDA HZ vaccination recommendations?; (b) Are NYULH
physicians adhering to current FIZ vaccination recommendations?; (c) What are NYUTFI
physician s attitudes towards the HZ vaccine?; and (d) Are NYIJLI1 physician's attitudes
barriers to HZ vaccination? (1 sui et ah, 2018). To answer these research questions, a
cross-sectional online survey was distributed through email to 530 faculty members
across five different practice settings of the Division of General Internal Medicine and
Clinical Innovation at NYULH. The study was conducted from February 2017 to March
2017 (Tsui et ah. 2018).
Tsui et ah (2018) reported a total response rate of 26% (138/530) across the 5
clinics. Among the responders, over 95% were aware of the CDC's recommendation for
the HZ vaccine for individuals age 65 or 70 years, including if they are on medications
for heart disease, diabetes, or hypertension. Even a history of HZ is permissible within
the CDC's recommendation. Comparatively, only 63% were aware of the FDA's
approval for immunocompetent individuals 50 years and older to receive the HZ vaccine.
Of the self-reported practice patterns, 43% of the patients 60 years and older were
reported as receiving the HZ vaccine. Only 11% of patients 50 years to 59 years had
received the HZ vaccine. In contrast, 72% of patients received the pneumococcal vaccine
and 67% of patients received the influenza vaccines (P< 0.001. respectively). Physician
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lepoited cost of the vaccine was a primary barrier. A high percentage of physicians (91%,
121/1 JJ) recommended HZ vaccination for immunocompetent patients age 60 years and
older. Only 76% of responders agreed that the HZ vaccine was clinically important
compared to the 94% lor pneumococcal vaccination importance and the 93% for
influenza vaccination importance. Over half of physicians believed that patients age 60
years and older should receive the HZ vaccine. However, only 36% of physicians
believed that patients 50 years and older should receive the HZ vaccine.
Chaudhry et al. (2013) conducted a study at four clinical sites in the Rochester
area that employed 45 general internists, 40 family doctors, 96 internal medicine
residents and 20 family medicine residents, and provides primary care to 140,000
patients. When Chaudhry et al. (2013) began their implementation of the clinical decision
support system, the workflow for addressing the preventive services for patients began
with the licensed practical nurses, who showed the patient to his or her room, checked
vital signs and medications, and checked the necessity of age-specific preventive
services. The researchers developed a web-based application that used Gh Web services
and a MSQweb.net platform to retrieve patient vital statistics, weight and body mass
index, age. demographic information, prior diagnoses, allergies and previous services.
This method included a rules-based application in which national guidelines for agespecific criteria were applied to the individual patient s biostatistics. Hie application
would alert the provider if a need for the vaccination was indicated, ll the patient
accepted the provider's recommendation for vaccination, the nurse vaccinated the patient
at the end of the visit (Chaudhry et al., 2013).
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Chaudhry et al. (201 J>) used billing information to calculate the number of HZ
vaccinations administered in the Primary Care Internal Medicine and Family Medicine
clinics. In a one-year time span, rates started at 63 and increased to 117 vaccinations after
a one-month period of clinical support software implementation, which was a 53.8%
inciease in vaccination adherence. At the time of their study, there were no other practice
improvement initiatives underway at any of the practices related to the HZ vaccine. The
two most proven methods reported in the literature are a provider recommendation for
immunization and protocols that allow nurses and allied health staff to screen the patients
and vaccinate them, if indicated. The approach of nursing staff providing the vaccination
has been proven to be the most beneficial.
Chaudhry et al. (2013) sought to determine the reason for decreased
implementation of preventive services in the US, with up to 50% of patients not receiving
age-specific, preventative services, or care for their chronic conditions. The researchers
reported a study of attitudes of primary care doctors toward vaccination and perceived
barriers and found that 22% believed that their eligible patients did not need the vaccine.
Further exploration for why PCPs did not believe their patients were eligible was not
addressed, but provider beliefs are known to play an important role in whether patients
receive vaccinations. PCPs lack of knowledge could have been a contributing factor. Our
current study will seek to determine Mississippi PCP's awareness of the
recommendations of RSV for adults aged 50 years and older.
Chaudhry et al. (2013) sought to determine the utilization of FIZ vaccine before
and after the implementation of a web-based clinical decision support software solution
in a primary care practice. HZ is a localized neurocutaneous eruption of blisters caused
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by reactivation of the VZV. I he cost of care for HZ and its complications is estimated as
$1.1 billion. The CDC AC1P recommends one-time dose of the vaccine for adults aged
60 years or older. The 2017 recommendation from the CDC is that adults 50 years of age
and older receive the new vaccination, Shingrix. This vaccination is administered in two
doses, within 2 to 6 months after the first dose. Despite the recommendation, utilization
of the vaccine is very low. One method to increase the practice of preventive services
such as vaccinations is with a computerized clinical decision support system. The
researchers found that the HZ vaccination rate increased significantly after the
implementation of such a system.
Elkin et al. (2011) surveyed general internal medical physicians (CJIM) from
October to December 2011 before interventions and one year later to increase the use of
HZ vaccine by studying the knowledge, attitudes, practices and perceived obstacles of
physicians after interventions to overcome barriers. The researchers hypothesized that by
introducing interventions that influenced GIM physicians knowledge and attitudes in
relation on the HZ vaccine, there would be a change in provider practices to increase the
use of the HZ vaccine in eligible patients.
Following analysis, the researchers found the average monthly HZ vaccine usage
in the New York University pharmacy increased 156% in the 10 months between the two
surveys when compared with the 3 months prior to the baseline survey and interventions.
Of the physicians that participated in both surveys, they were statistically more likely to
know there were greater than 1,000,000 cases of HZ annually in the US and to report
physician education regarding the severity of HZ. Significant differences in physician
attitudes and practices remained the same among the four different provider sites in both
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surveys. I he Bellevue Hospital and Gouverneur Healthcare Services (B/G) and voluntary
practice services (Vol) were more likely to report cost as a barrier. B/G expressed greater
difficulty with order and administration of the HZ vaccine, due to no available formulary
for the vaccine, which resulted in B/G physicians responding that less than 10% of their
patients received the HZ vaccine. As with the prior SPS, four years later the efficacy
remains, but the reduction of illness decreased to 50.1% from 61%. Among eligible
patients, improving HZ vaccination rates remained a clinical priority (Elkin et ah, 2011).
Elkin et al. (2011) were able to improve awareness of the underutilization of the
HZ. despite the continued support of its efficacy and safety. Simple interventions like a
nurse present at the pharmacy to administer the vaccine and nurse-initiated prompting
may increase the usage of the HZ vaccine and physician recommendation for the vaccine.

CHAPTER III
Methodology
The purpose oi the current research was to determine PCP knowledge and
practices oi the ACIP's recommendations for the Shingrix vaccination in patients 50
years and older. Shingrix is the ACIP's preferred vaccination to prevent the occurrence of
shingles and its potential consequences, such as PHN. Shingles affects one in three
persons within their lifetime. Following this section, this chapter will discuss the design,
setting, population and sample, methodology, and data analysis used to conduct the
research.
Design of the Study
The researchers utilized a descriptive, quantitative survey design to evaluate PCP
knowledge and practices of the ACIP's recommendation for administering the HZ
vaccination in people 50 years of age and older. Data for this research project was
collected from 54 healthcare providers via surveys provided through the electronic
database Survey Monkey, digital surveys through email and social media, and written,
hand-delivered surveys to qualifying participants. This research was utilized to show
results from a nonexperimental study that described aspects of Mississippi PCP
knowledge and practices regarding the Shingrix vaccination. This design study was most
appropriate given the time constraints for collecting data, the accessibility of participants
responding, and the likelihood of obtaining quality information that cannot be extracted
from a compliance audit (e.g. perceived barriers and attitudes). The online and written
survey allowed the researchers to access and receive responses from 1 CPs across
Mississippi instead of a localized area within Mississippi.
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Setting for the Research Project
1 he research study was conducted in multiple primary care clinics located
throughout Mississippi. Surveys were distributed to physicians, nurse practitioners, and
physician assistants utilizing Survey Monkey's online application, email, social media,
and hand delivered paper surveys. For social media utilization and email, the links to the
survey were posted to various professional closed-member group sites for physicians,
nurse practitioners, and physician assistants or emailed to physicians, nurse practitioners,
and physician assistants to reduce the possibility of unqualified subjects completing the
survey. The hand delivered paper surveys were distributed in sealable envelopes by the
four members of the researcher group conducting the study to ensure privacy.
Population and Sample
The population for the research were PCPs from Mississippi. The population
included the following disciplines: medical doctors, physician assistants, doctors of
osteopathy, and nurse practitioners. 1 he sample population of Mississippi PCPs was 54.
The researchers utilized a convenience sampling by email distribution and messaging
online via social media, and hand-delivered written surveys.
Methods of Data Collection
Permission to conduct the study was obtained from the Institutional Review
Board at Mississippi University for Women prior to ignition ol lesearch. Humans subject
were used when asking PCPs in Mississippi to complete a questionnaire regarding the
individual's current practices regarding the ACIP s recommendation for the Shingrix
vaccine for adults aged 50 years and older. During data collection for the research study,
anonymity was maintained via non-traceable Survey Monkey technology and sealable

28

envelopes with a return address. No personal patient information was collected on the
questionnaire or data collection forms, nor was data saved on computer hard drives. Upon
compiling data for analysis, data was stored on a single jump drive that was locked in a
researcher's filing safe.
On completion of the research study, the jump drive containing all collected data
was destroyed. The Survey Monkey account was deleted, and the data maintained on the
site was removed according to the website policy. The researchers utilized Survey
Monkey to host the survey and maintain the data collected for the duration of the research
study. The survey consisted of researcher developed questions (see Appendix). The
researchers gathered data regarding PCP self-reported practices related to knowledge and
practices of the ACIP's recommendations. The survey contained multiple choice
questions. On the survey, questions 1-6 requested demographic data and questions 7-16
were related to AC1P recommendations, Shingrix vaccination, and adherence. The
question and answer options for each question were developed and selected based on
current literature regarding PCP knowledge and practice to ACIP recommendations or
guidelines. The questionnaire did not undergo psychometric testing but faced validity
based on a panel of expert researchers.
Methods of Data Analysis
Data was compiled following the conclusion of the survey. The data collected
from the surveys represented the nominal measurements from the multiple-choice format
questions. Parameters were calculated for each question and displayed as a percentage.
These percentages were used to assess the sample population's knowledge and practice of
the ACIP's recommendations for the Shingrix vaccination in adults aged 50 years and
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older. The demographic data obtained was used to help identify any trends that may exist
in Mississippi PCPs' Shingrix practices. Findings to research questions were reported
using descriptive statistics and percentages.

CHAPTER IV
Presentation of the Findings
Data collected from the survey are presented in this chapter with respect to the
research questions in C hapter I. I his information will be informative in identifying the
practices and knowledge of PCPs in Mississippi concerning the Shingrix vaccine.
HZ is a preventable disease that affects 1 in 3 people over their lifetime. A
severely painful complication called PHN occurs in up to 20% of people affected with
shingles. 1 he CDC ACIP recommends, and prefers a recombinant zoster vaccine
(Shingrix) with a greater than 90% efficacy rate for preventing shingles for
immunocompetent adults aged 50 years and older. The researcher's main objectives were
to determine Mississippi PCPs' knowledge and practices of the CDC ACIP
recommendations for administering the Shingrix vaccine to immunocompetent adults
aged 50 years and older.
The results of this study were collected from an online survey via social media
and hand-delivered written surveys. Survey questions addressed the demographic data
regarding participant's age, years of experience, gender, title, type of community served,
type of insurance accepted, and electronic health record (EI IR) prompting for zoster
vaccination. Questions also addressed PCP's knowledge and practice of ACIP's most
recent Shingrix recommendations and administration parameters, knowledge of
Shingrix's effectiveness at decreasing incidence of shingles and peripheral herpetic
neuralgia, and importance of the Shingrix vaccine compared to the flu and pneumonia
vaccines. Shingrix's cost-effectiveness and efficacy compared to Zostavax was surveyed,

30

along with self-reported barriers to recommending the Shingrix vaccine. The presentation
ot the findings

includes the profile of the study participants and the statistical results.

Profile of Study Participants
A total of 54 PCPs from multiple clinics within Mississippi via a voluntary,
anonymous online survey and hand-delivered written survey responded to the survey.
Demographics of the respondents and their representative clinics are shown in Table 1.
Most of the respondents were advanced practice nurses totaling 88.9% (77 = 48). Of the
remaining respondents surveyed. 9.3% (.77 =5) were MDs, while 1.9% (72 = 1) of the
respondents were DOs. There were no PA respondents noted.
Most participants were of the female gender totaling 87% (77 = 47). I he majority
of the respondents were 30-44 years of age at 59.3% (72 = 32). The remaining age groups
of 45-59 years of age totaled 24.1% (.77 = 13), 20-29 years of age totaled 11.1% (72 = 6),
and 60+ years of age totaled 5.6% (ll = 3).
Respondents with less than five years of experience totaled the highest at 38.9%
(77 = 21). Respondents with 20-29 years of experience totaled next highest at 25.9% (72 =
14). Respondents with experience of 5-10 years and 10-19 years totaled equally at 16.7 A
(77= 9) and 16.7% (77 = 9). Most respondents practice in rural clinics 70.4% (72= 38). The
remaining respondents totaled at 18.5% (72= 10) urban clinics and at 11.1% (72= 6)
suburban clinics.
Most respondents accepted federal and state insurance totaling at 40.7% (72 = 22).
The remaining respondents that accepted both federal/state and private insurance totaled
at 31.5%

(72=

17), while 22.2%

insurance. Lastly, 5.6%

(72

(72=

12) of the respondents only accepted private

= 3) of the respondents accepted no insurance.
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Table 1

Demographics of Survey Respondents (N=54)
Number of Respondents
Title
NP
MD
DO
Gender
Female
Male
Age
20-29 years
30-44 years
45-59 years
60+ years
Experience
<5 years
5-10 years
10-19 years
20-29 years
Location
Rural
Suburban
Urban
Insurance Accepted
None
Private
Federal/State
Both

% of Respondents

48
5
1

88.9
9.3
1.9

47
7

87.0
13.0

6
32
13
oJ

11.1
59.3
24.1
5.6

21
9
9
14

38.9
16.7
16.7
25.9

38
6
10

70.4
11.1
18.5

oJ

5.6
22.2
40.7
31.5

12
22
17

Statistical Results
As mentioned in Chapter 1, the researchers posed the following two questions:
1. Are Mississippi primary care providers knowledgeable about the Advisory Committee
on Immunization Practices' Shingrix recommendations for patients age 50 years and
older?
2. What are the Shingrix practices of Mississippi primary care providers?

In order to answer the research questions, a 17-question survey was distributed
via voluntary, anonymous online social media link and hand-delivered written surveys.
The results are presented in the following sections.
Question 1: Are Mississippi primary care providers knowledgeable about the
Advisory Committee on Immunization Practices' Shingrix recommendations for
patients age 50 years and older?
Question 8 of the survey was used to analyze this question. Respondents were
asked, '•Are you aware of the ACIP's recommendations from October 2017 to

recommend Shingrix as the preferred vaccine to immunocompetent adults aged 50years
and older?" Of the 54 respondents, 85.2% answered "Yes," indicating that they were
aware of the ACIP's recommendations. The awareness rates were highest for those
practitioners with more experience, as shown in Table 2. There was no statistical
difference in awareness rates based on title, gender, age, location, or insurance.
Table 2

ACIP Recommendation Awareness by Years of Experience
% of Yes Reponses
N
Experience
71.4%
21
<5 years
77.8%
9
5-10 years
100.0%
9
10-19 years
100.0%
14
20-29 years
85.2%
53'
Overall
'Note: Only 53 respondents answered the awareness question.
Question 2: What are the Shingrix practices of Mississippi primary care
providers?
Question 9 on the survey addressed practices of PCPs' Shingrix
recommendations. Respondents were asked to rate their agreement to the statement, 7
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recommend the Herpes Zoster subunit (Shingrix) to immunocompetent adults aged 50
years and older. " Of the 54 respondents, 20.4% reported "Always," 37.0% reported
"More than 50%," 27.8% reported "Less than 50%," and 13.0% reported "None." There
was no statistically significant difference in respondent ratings based on title, gender, age,
years of experience, location, or insurance.
Question 7 on the survey addressed HER prompting. Respondents were asked, "Is

there prompting in your EHR for recommending the Zoster vaccine to patients?" Of the
54 respondents, 1 8.5% reported "Yes," and 81.5% reported. "No." There was no
statistically significant difference in responses based on title, gender, age, years of
experience, location, or insurance.
Question 10 on the survey addressed exclusionary criteria for Shingrix
administration. Respondents were given a list of possible criteria; the most commonly
selected response was "Pregnant or lactating women (70.4%)." The second-most
commonly selected response was "Immunocompromising illness (63.0%)," followed by
"Persons taking moderate to high doses of immunotherapy (50.0%)," and "Persons who
are VZV seronegative (35.2%)."
Other Findings
Questions 11, 12, 13, 14, 15, and 16 addressed the Shingrix vaccine and the ACIP
recommendations. Respondents were asked to rate their level of agreement with the six
statements. Table 3 shows the frequency of responses for the six statements. The most
common response on the first the items was "Strongly Agree." The most common
response on the last three items was Neither Agree noi Disagree.
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Table 3

Frequency of Responses to Vaccine and ACIP Recommendation Statements (N=54)
Statement

o
(* i
ZJ

Shingrix vaccine is effective at
decreasing the incidence of peripheral
herpetic neuralgia.
Shingrix vaccine is effective at
decreasing incidence of shingles.
The Shingrix vaccine is comparatively
important to the flu and pneumo vaccine
for the health of patients aged 50 years
and older.
The ACIP and the CDC's vaccination
recommendations are important to
adhere to in the health promotion and
disease prevention of patients.
The recombinant Shingrix vaccine is
more cost-effective than the liveattenuated Zostavax vaccine.
Shingrix's efficacy is better than
Zostavax.
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5.6%
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1.9%
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33.3%
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0.0%

5.6%

48.1%

25.9%

20.4%

0.0%
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25.9%
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22.2%
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Question 17 addressed barriers for not recommending the Shingrix vaccine to
immunocompetent patients age 50 years and older. Respondents were asked to lank-ordei
seven possible barriers for not recommending the Shingrix vaccine. The lating of 1
designated the most important barrier. Table 4 shows the results of the ranking. The most
important barrier ranked was "Cost to patient by 25 respondents (46.3 /o) and leceived
the lowest average rank (2.10). The order of important of the other barriers, by average
rank, were "Uncertainty about eligibility (3.27),'' "Lack of time (3.29),
(4.04)," "Injection site reactions (5.25)," and "Other (6.00)."

Side effects
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Table 4

Barrier Ranking Results
Barrier
Lack of time
Cost to patient
Uncertainty about
eligibility
2-dose scheduling
Side effects
Injection site reactions
Other

1

2

3

4

5

6

7

12
25
5

9
11
11

6
8
15

7
4
8

4

8

o
J

0

5

4

2
1
1

o
J

9
6
4
1

7
9

15
7
5

9
22
6
1

4
2
28
2

1
2
6
25

O
J

1
1

o
J
o
J

n
3

Ave rag
Rank
3.29
2.10
3.27
3.71
4.04
5.25
6.00

CHAPTER V
Summary and Conclusions
As the incidence of HZ increases, the goal of prevention is essential. The goal of
this research study was to determine if Mississippi PCPs are knowledgeable of the ACIP
Shingrix recommendations for patients age 50 years and older, and the Shingrix practices
of Mississippi PCPs. The current research study surveyed a sample of 54 PCPs from
multiple clinics in Mississippi to determine if Mississippi PCPs adhere to the CDC's
ACIP s recommendations for administering the Shingrix vaccine to immunocompetent
adults aged 50 years and older.
Related research studies, previously reviewed in Chapter II, indicated that the
HZVs are effective in the prevention of HZ and PHN. The articles focused on barriers to
providing vaccines, the knowledge of vaccines, and the effects of vaccines. As this study
focused on Mississippi PCPs knowledge of recommendations and practices, the results of
prior related research assisted in the development of the research survey and provided
confirmation of findings. These studies will be referenced further in the summary of
findings section.
The data analysis summary, discussion of the findings, and the limitations of this
research study are presented in this chapter. In conclusion, an interpretation of the results,
implications to support further education, and additional recommendations toi luture
research will be discussed.

Summary of the Findings
Demographic data revealed that the majority of the 54 respondents were nurse
practitioners in Mississippi. The other participants identified their provider type as MD or
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DO. All surveys weie sent to PCPs in MS, indicating that the findings are reflective of
practices among family care.
The results of the survey indicated that 85.2% of the respondents were aware of
the ACIP s recommendations. The rate of awareness was significantly different based on
years of experience of PCPs. The awareness rates were highest for those PCPs with more
experience.

1 here was no statistically significant difference in awareness rates based on

title, gender, age, location, or insurance.
When investigating the recommendation of the Shingrix vaccine to
immunocompetent adults aged 50 years and older, there was no majority leading in
recommendations. Of those surveyed. 20.4% reported they always recommend the
vaccine, 37.0% reported recommending greater than 50% of the time, 27.8% reported
recommending the vaccine less than 50% of the time, and 13.0% reported never
recommending the vaccine. In comparison with previous studies, the findings were
similar. Although PCPs were aware of the recommendations of the CDC, ACIP. or FDA
for administering the HZV, the rates of actual recommendation remain low. In review of
previous literature and the current research finding, there seemed to be common barriers
for lack of recommendation including; vaccination cost, lack of PCP time, and a lack of
knowledge regarding the HZV.
The researchers also sought to determine if PCP used EHRs to prompt them to
recommend the zoster vaccine to patients. Of the respondents, the larger amount reported
that they are not prompted by their EFIR to recommend the HZV. It is not clear why HZV
prompting is not standard in EHR. However, as revealed by previous studies, the addition
of this simple prompt to EHRs would increase the number of HZV recommendations,
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possibly increasing the number of HZVs administered and decreasing the incidence of
HZ and PHN.
1 urthermore, the researchers investigated through the survey PCPs' exclusionary
criteiia for administering the vaccine, their level of agreement with statements regarding
the Shingrix vaccine and ACIP s recommendation, and barriers to recommending the
vaccine. 1 he most selected exclusionary criteria were pregnant and lactating women,
followed by persons with immunocompromising illness, then those receiving moderate to
high doses of immunotherapy, and finally persons who are VZV seronegative.
Researchers found that the surveyed PCPs strongly agree with the effectiveness of
Shingrix vaccine decreasing the incidence of shingles and PHN. They also strongly agree
that Shingrix vaccine is comparatively important as the flu and pneumococcal vaccine in
patients aged 50 years and older. However, the majority of the surveyed PCPs neither
agreed nor disagreed with the importance of adhering to the vaccination's
recommendation by CDC and ACIP for health promotion and prevention. Nor did they
agree or disagree regarding the cost-effectiveness and efficacy ol the vaccines when
comparing Shingrix to the other shingles vaccine Zostavax. When evaluating the
importance of barriers to recommending the Shingrix vaccine, it was discovered that the
most important barrier was the cost to the patient followed by uncertainty of eligibility,
lack of time, 2-dose scheduling, side effects, and injection site reactions.
Discussion of Findings
The CDC ACIP recommendations suggest the administration of Shingrix vaccine
to immunocompromised adults aged 50 years and older. The researchers concluded that
roughly 85% of Mississippi PCPs surveyed were knowledgeable about these
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recommendations. In contrast, Mississippi PCPs had a low compliance of 20.4% for
consistently offering the Shmgrix vaccine. Several barriers were also presented and rated
by the Mississippi PCPs that were surveyed.
Health promotion can lead to healthy behavior, increased health status and
decreased cost in healthcare. Researchers found that when utilizing Pender's HPM, PCPs
can prevent 01 predict events that may interfere with health promoting behavior.
Pender s HPM has been shown to be a workable model in the intervention development,
prevention ol unhealthy choices, changing practices and promoting healthy activity
(Heydari & Khorashadizadeh, 2014). Although research showed that health promotion
and disease prevention is essential, research revealed that Mississippi PCPs in this study
neither agreed or disagreed with the importance of vaccination recommendations of the
AC1P and the CDC for health promotion and disease prevention.
In review of the practices of PCP with EHR prompting, Chaudhry et al. (2013)
sought to study utilization of HZ vaccine before and after the implementation of a webbased clinical decision support software solution in a primary care practice when the
CDC ACIP was recommending a one-time dose of the vaccine for adults aged 60 years or
older. In October 2017 recommendations from the CDC were changed for adults 50 years
of age and older to receive the new vaccination, Shingrix. I his vaccination is
administered in two doses, within 2 to 6 months after the first dose. Despite the
recommendation, utilization of the vaccine is very low. One method to increase the
practice of preventive services such as vaccinations is with a computerized clinical
decision support system. Chaudhry et al. (2013) found that the HZ vaccination rate
increased significantly after the implementation oi such a system. Our study lound that
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only 18.5% of the o4 responders EHR prompted them to recommend the Zoster vaccine.
With implementation of EHR prompting for Zoster vaccination for Mississippi PCPs
there could be an increase in administering the Zoster vaccine, thereby decreasing the
incidence of shingles and PI IN.
Despite recommendations from the CDC and ACIP to provide HZV, there
remains multiple barriers. O Donnell et al. (2018) performed a study revealing that
although zostei vaccination was recommended by the CDC for immunocompetent adults
50 years ot age and older, and its efficacy has been demonstrated. 11ZV usage continued
to be low. I he studies further revealed concerns of cost for the patient and provider,
safety, and lack ol knowledge regarding HZV, with the primary barrier identified as a
lack of knowledge in multiple areas concerning the HZV. These findings were
inconsistent with the results of the current research, which identified cost as the primary
barrier that hindered the PCPs compliance with ACIPs recommendations.
In addition, Tsui et al. (2018), performed a survey to evaluate the knowledge,
attitudes, and practices for the HZ vaccine of providers within five clinics of the NYU
Langone Health (NYULH) clinics. While the majority of the respondents were aware of
the HZV recommendations according to the CDC for ages 65-70 years, there was a
comparatively fewer amount aware of the FDA's approval of the HZV at the age of 50.
Physician attitudes regarding barriers showed that cost of the vaccine was the top
reported barrier. The researchers also reported that a considerably large number of
responders agreed that the HZ vaccine was comparatively important to the pneumococcal
and influenza vaccination. When compared to the current study, these findings varied in
consistency. While the PCP in the study lacked knowledge of recommendations at age
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50, the respondents m the current study were found to be knowledgeable of the
recommendation at age 50. The referenced study revealed that the responders strongly
agreed that the Shingnx vaccine is comparatively important to the flu and pneumococcal
vaccine in patients aged 50 years and older, as did those in the current study. Finally,
both studies reveal cost to the patient as the most important barrier to recommending
HZV.
Limitations of the Study
1 he researchers assert that one of the limitations of this study was a small sample
size due to lack oi survey responses. There was also a time constraint. The survey was
opened for a limited time of approximately 2 months. This study relied on PCPs' selfreporting instead of a calculated measurement from chart reviews that impartially
document the PCP practices or observed practices. Another limitation was the inability to
generalize results based on the sample participants not being representative of all
providers collected at a single point in time due to the study being restricted to
Mississippi and PCP. There was also the limitation of the majority of the respondents
being female nurse practitioners from rural areas, thus limiting the types of providers
surveyed.
Conclusion
The goal of the current research was to determine if Mississippi PCPs were
knowledgeable about the CDC AC IP Shingrix recommendations for patients aged 50
years of age and older. The current research also sought to determine if Mississippi PCPs
are adhering to ACIP's Shingrix recommendations for patients aged 50 years and older.
According to the results, the researchers determined Mississippi PCPs' knowledge of

CDC guidelines were sufficient. Of the 54 respondents, the results indicated that 85.2%
were knowledgeable. Additionally, response rates varied regarding Mississippi PCPs'
adherence to recommending the vaccine to patients aged 50 years and older. Of the 54
respondents, only 20.4% reported always recommending the Shingrix vaccine to
immunocompetent adults aged 50 years and older, with 13% reporting not recommending
at all.
I he results ot the survey indicated that the most common barrier for not
recommending was cost to the patient. While this study does not determine if Mississippi
PCPs are aware ol the actual cost to the patient, or if their assumptions of the cost is the
reason for the decrease in recommending this vaccine, this finding does indicate a
significant need for further education of the Shingrix vaccine. If patients were better
educated on the benefits of the Shingrix vaccine and the potential side effects of the HZ
vaccine, cost may not be an issue for the patient.
Implications

According to the CDC recommendations, the Shingrix vaccine is recommended
for use in immunocompetent adults aged 50 years and older. I his study concluded
Mississippi PCPs possess an increase in knowledge of the Shingrix vaccine, yet they have
decreased compliance in regard to recommending Shingrix to their patients. The
researchers inferred that Mississippi PCPs need additional education on the benefits oi
Shingrix vaccine as well as the potential painful, long-term side effects of HZ. With
further education, Mississippi PCPs could further understand the efficacy of Shingrix
vaccine, which could improve the overall health and well-being of their patients. I his
study was guided by Nola Pender's HPM which, in summary, focuses on identifying
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factors that could influence or hinder health. Mississippi PCPs should educate their
patients on the 1IZ virus and the beneficial aspects of receiving Shingrix vaccine to either
prevent the HZ virus or minimize or eliminate its side effects.
Recom mendations
Based on the outcomes of this study, the following recommendations are made for
practice:
1. Construct a visual education model to display to Mississippi PCPs and to
patients about the harmful effects of HZ virus, including the possible long-term
effects of PHN.
2. Construct an additional education model to demonstrate the benefits of
Shingrix vaccine.
3. Develop a program to prompt Mississippi PCPs to screen all potential patients
for the Shingrix vaccine.
4. Develop a quick reference guide of co-pays for common insurance carriers to
determine the cost to the patient for the Shingrix vaccine.
Summary
The current researchers, as reported in Chapter V. revealed that Mississippi PCPs
are deficient in compliance of the CDC ACIP recommendations of Shingrix vaccine to
immunocompetent adults aged 50 years and older, yet a vast majority of the Mississippi
PCPs surveyed possessed the knowledge of the Shingrix vaccine. 1 he researchers also
determined cost of the vaccine as the primary barrier to Mississippi PCPs recommending
Shingrix to patients. An increase in patient education about the potential long-term side
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effects of HZ and the benefits of Shingrix vaccine could break the bar rier of cost, thus
leading to an increase ot the number of patients preferring and receiving vaccination.
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APPENDIX
Awareness and Adherence to ACIP's Shingrix Recommendation Worksheet
Among Mississippi Primary Care Providers
1. What is your title?
. MD
•

DO

•

NP

•

PA

2. Gender
•

Male

•

Female

3. What is your age?
•

20-29 years

•

30-44 years

•

45-59 years

•

60+ years

4. How many years of experience?
•

<5 years

•

5-10 years

•

10-19 years

•

20-29 years

•

>30 years
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5. What type of community do you serve?
•

Rural

•

Suburban

•

Urban

6. What type of insurance do you accept?
•

Private

•

Federal or State

•

None

7.1 recommend the 1 lerpes Zoster subunit (Shingrix) to immunocompetent adults aged
50 years and older.
•

Always

•

More than 50%

•

Less than 50%

•

None (If not. please specify)

8. Are you aware of the AClP's recommendations from October 2017 to recommend
Shingrix as the preferred vaccine to immunocompetent adults aged nO years and older ?
•

Yes

•

No

9. Which of the following are the exclusionary criteria for Shingrix? Select all that apply.
•

Persons taking moderate to high doses of immunotherapy

•

Persons who are VZV seronegative

•

Persons who presently have an immunocompromising illness

•

Pregnant or lactating women
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10. Is there prompting in your ElIR for recommending the zoster vaccine to patients?
•

Yes

•

No

11. Shingrix vaccine is effective at decreasing incidence of shingles.
•

Strongly agree

•

Agree

•

Disagree

•

Strongly disagree

12. Shingrix vaccine is effective at decreasing the incidence of peripheral herpetic
neuralgia.
•

Strongly agree

•

Agree

•

Disagree

•

Strongly disagree

13. The Shingrix vaccine is comparatively important to the flu and pneumococcal vaccine
for the health of patients aged 50 years and oldei.
•

Strongly agree

•

Agree

•

Disagree

•

Strongly disagree

14. The ACIP and the CDC's vaccination recommendations are important to adhere
the health promotion and disease prevention of patients.
•

Strongly agree

•

Agree

•

Disagree

•

Strongly agree

15. The recombinant Shingrix vaccine is more cost-effective than the live-attenuated
Zostavax vaccine.
•

Strongly agree

•

Agree

•

Disagree

•

Strongly agree

16. Shingrix's efficacy is better than Zostavax.
•

Strongly agree

•

Agree

•

Disagree

•

Strongly agree

17. Rate the following barriers in order of importance (1 being the most important) 1
not recommending Shingrix.
•

Lack of time due to other priority tasks foi each patient \isit

•

Cost to patient

. Hesitant to vaccinate due to uncertainty about patient's eligibility to receive
vaccination.
•

Hesitant to vaccinate due to Shingrix's 2-dose scheduling

•

Hesitant to vaccinate due to Shingrix s potential side

•

Hesitant to vaccinate due to injection site reactions

Other barriers [ Please comment]

